암 분자진단 시장 : 암 유형별, 제품 유형별, 지역별 예측 - Executive Consultant Guide(2024-2028년)

OVERVIEW:

Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 140 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

• personalized medicine
• pharmacogenomics
• liquid biopsy
• minimal residual disease testing
• emergence of new economies with large markets
• physician diagnostics being displaced by new intelligent diagnostic tests

Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

• B.Sc. (Chemistry) University of BC
• M.B.A. (Finance and Policy) University of BC
• Market Research Seminar - Burke Institute
• Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

• 1.1 Cancer MDx - Strategic Situation Analysis
• 1.2 Guide for Executives, Marketing, and Business Development Staff
• 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

• 2.1 What are Molecular Diagnostics?
• 2.2 The Diagnostics Revolution
• 2.3 Market Definition
  • 2.3.1 Revenue Market Size
• 2.4 Methodology
  • 2.4.1 Methodology
  • 2.4.2 Sources
  • 2.4.3 Authors
• 2.5 Perspective: Healthcare and the IVD Industry
  • 2.5.1 Global Healthcare Spending
  • 2.5.2 Spending on Diagnostics
  • 2.5.3 Important Role of Insurance for Diagnostics

3 Market Overview

• 3.1 Market Segments
  • 3.1.1 Traditional Market Segmentation
  • 3.1.2 Laboratory Focus and Segmentation
• 3.2 Industry Structure
  • 3.2.1 Hospital Testing Share
  • 3.2.2 Economies of Scale
  • 3.2.3 Physician Office Lab's
  • 3.2.4 Physician's and POCT

4 Market Trends

• 4.1 Factors Driving Growth
  • 4.1.1 New Diagnostics Create New Markets
  • 4.1.2 New Roles for Diagnostics
  • 4.1.3 Aging Effect
  • 4.1.4 Expanding the Pharmaceutical Toolbox
  • 4.1.5 Regulatory Retreat
• 4.2 Factors Limiting Growth
  • 4.2.1 Falling Prices
  • 4.2.2 Lower Costs
  • 4.2.3 Wellness has a Downside
• 4.3 Instrumentation, Automation and Diagnostic Trends
  • 4.3.1 Traditional Automation and Centralization
  • 4.3.2 The New Automation, Decentralization and Point Of Care
  • 4.3.3 Instruments Key to Market Share
  • 4.3.4 Bioinformatics Plays a Role
  • 4.3.5 PCR Takes Command
  • 4.3.6 Next Generation Sequencing Fuels a Revolution
  • 4.3.7 NGS Impact on Pricing
  • 4.3.8 Whole Genome Sequencing, A Brave New World
  • 4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
  • 4.3.10 Shifting Role of Diagnostics
  • 4.3.11 Multiplexing and Foundation One
  • 4.3.12 Pharmacogenomics Technology
  • 4.3.13 Gene Editing and Gene Therapy

5 Molecular Diagnostics Recent Developments

• 5.1 Recent Developments - Importance and How to Use This Section
  • 5.1.1 Importance of These Developments
  • 5.1.2 How to Use This Section
• 5.2 Foundation Medicine, Repare Therapeutics to Develop CDx
• 5.3 NHS Declines to Accelerate Grail Galleri Implementation
• 5.4 GeneDx Sees Growing Demand for Testing
• 5.5 Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
• 5.6 ClearNote Health Expands Into Immunotherapy Monitoring
• 5.7 Foundation Medicine to Collaborate on CDx for Lung Cancer
• 5.8 Qiagen and Myriad Genetics Partner to Develop Cancer CDx
• 5.9 Lung Cancer Data Heralds Shift for Hummingbird Dx
• 5.10 PamGene Awarded Euro-7.5M for Immunotherapy Test
• 5.11 Grail Cancer Test Faces New Clinical Questions
• 5.12 Freenome Acquires Cancer Dx Firm Oncimmune
• 5.13 Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology
• 5.14 Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients
• 5.15 Digital Pathology Meets Cancer Sequencing
• 5.16 Exact Sciences Preps Expanded Oncology Portfolio
• 5.17 Qiagen Details Oncology Plans for Digital PCR Platform
• 5.18 Sema4 Exiting Reproductive Health Screening
• 5.19 Thermo Fisher Introduces Cancer Profiling Assay
• 5.20 Genomic Test IDs Cysts Likely to Progress to Cancer
• 5.21 Naveris to Commercialize Virus-Related Cancer Tests
• 5.22 Larger Liquid Biopsy Panels Loom
• 5.23 Halo Diagnostics to Offer Genomic Profiling Tests
• 5.24 BillionToOne Raises $125M
• 5.25 Local Cancer Genomic Profiling Options Grow
• 5.26 German MDx Firm Mainz Biomed Raises $10M in IPO
• 5.27 Guardant Health Q3 Revenues Up 27 Percent
• 5.28 BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection
• 5.29 Nucleix to Invest in Early-Stage Lung Cancer Dx
• 5.30 Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics
• 5.31 Grail Gets Approval for Galleri Multicancer Test
• 5.32 Finnish Firms to Form Point-of-Care Testing Firm
• 5.33 Datar Cancer Genetics Expands to Dx and Screening
• 5.34 HTG Molecular Diagnostics: HTG Transcriptome Panel
• 5.35 PacBio's Omniome Acquisition Shortens Path to Clinical
• 5.36 Invitae to Acquire Genosity for $200M
• 5.37 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
• 5.38 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
• 5.39 Natera Revenues Grow 35 Percent
• 5.40 AnchorDx Closes $40M Financing Round
• 5.41 Exact Sciences Strategy for End-to-End Cancer Testing
• 5.42 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch

6 Profiles of Key MDx Companies

• 6.1 10x Genomics, Inc.
• 6.2 Abbott Laboratories
• 6.3 AccuraGen Inc.
• 6.4 Acuamark Diagnostics
• 6.5 Adaptive Biotechnologies
• 6.6 Admera Health, LLC
• 6.7 Aethlon Medical
• 6.8 Agilent
• 6.9 Amoy Diagnostics Co., Ltd.
• 6.10 Anchor Dx
• 6.11 ANGLE plc
• 6.12 ARUP Laboratories
• 6.13 AVIVA Systems Biology
• 6.14 Baylor Miraca Genetics Laboratories
• 6.15 Beckman Coulter Diagnostics (Danaher)
• 6.16 Becton, Dickinson and Company
• 6.17 BGI Genomics Co. Ltd
• 6.18 BillionToOne
• 6.19 Bioarray Genetics
• 6.20 Biocartis
• 6.21 Biocept, Inc.
• 6.22 Biodesix Inc.
• 6.23 BioFluidica
• 6.24 BioGenex
• 6.25 BioIVT
• 6.26 Biolidics Ltd
• 6.27 bioMerieux Diagnostics
• 6.28 Bioneer Corporation
• 6.29 Bio-Rad Laboratories, Inc
• 6.30 Bio-Reference Laboratories
• 6.31 Bio-Techne
• 6.32 Bioview
• 6.33 Bristol-Myers Squibb
• 6.34 Burning Rock
• 6.35 C2i Genomics
• 6.36 Cardiff Oncology
• 6.37 Caris Molecular Diagnostics
• 6.38 Castle Biosciences, Inc.
• 6.39 Celemics
• 6.40 CellCarta
• 6.41 CellMax Life
• 6.42 Cepheid (Danaher)
• 6.43 Charles River Laboratories
• 6.44 Circulogene
• 6.45 Cizzle Biotech
• 6.46 Clearbridge Biomedics
• 6.47 Clinical Genomics
• 6.48 Cytolumina Technologies Corp.
• 6.49 Datar Cancer Genetics Limited
• 6.50 Diagnologix LLC
• 6.51 Diasorin S.p.A.
• 6.52 Dxcover
• 6.53 Element Biosciences
• 6.54 Enzo Biochem
• 6.55 Epic Sciences
• 6.56 Epigenomics AG
• 6.57 Erythra
• 6.58 Eurofins Scientific
• 6.59 Exact Sciences
• 6.60 Fabric Genomics
• 6.61 Fluxion Biosciences (Cell Microsystems)
• 6.62 Freenome
• 6.63 FUJIFILM Wako Diagnostics
• 6.64 Fujirebio
• 6.65 Fulgent Genetics
• 6.66 Fyr Diagnostics
• 6.67 GeneDx Holdings
• 6.68 GeneFirst Ltd.
• 6.69 Genetron Holdings
• 6.70 GenomOncology
• 6.71 GILUPI Nanomedizin
• 6.72 Guardant Health
• 6.73 HansaBiomed
• 6.74 HTG Molecular Diagnostics
• 6.75 iCellate
• 6.76 ICON PLC
• 6.77 Illumina
• 6.78 Incell Dx
• 6.79 Inivata
• 6.80 INOVIQ
• 6.81 Invitae Corporation
• 6.82 Invivogen
• 6.83 Invivoscribe
• 6.84 J&J Innovative Medicine
• 6.85 Lucence Health
• 6.86 Lunglife AI Inc
• 6.87 MDNA Life SCIENCES, Inc.
• 6.88 MDx Health
• 6.89 Menarini Silicon Biosystems
• 6.90 Mesa Laboratories, Inc.
• 6.91 Metabiomics Corp
• 6.92 Millipore Sigma
• 6.93 Miltenyi Biotec
• 6.94 miR Scientific
• 6.95 Myriad Genetics
• 6.96 Nanostring
• 6.97 NantHealth, Inc.
• 6.98 Natera
• 6.99 NeoGenomics
• 6.100 NGeneBio
• 6.101 Novogene
• 6.102 Oncimmune
• 6.103 Oncocyte
• 6.104 OncoDNA
• 6.105 Oncohost
• 6.106 OraLiva
• 6.107 Oxford Nanopore Technologies
• 6.108 PamGene
• 6.109 Panagene
• 6.110 Personalis
• 6.111 Perthera
• 6.112 PGDx (Labcorp)
• 6.113 Precipio
• 6.114 PrecisionMed
• 6.115 Predicine
• 6.116 Predictive Oncology
• 6.117 Prenetics
• 6.118 Promega
• 6.119 Qiagen
• 6.120 QuidelOrtho
• 6.121 Rarecells SAS
• 6.122 RareCyte
• 6.123 Revvity
• 6.124 Roche Diagnostics
• 6.125 Screencell
• 6.126 Sherlock Biosciences
• 6.127 Siemens Healthineers
• 6.128 simfo GmbH
• 6.129 Singlera Genomics Inc.
• 6.130 Singular Genomics
• 6.131 Singulomics
• 6.132 SkylineDx
• 6.133 Standard BioTools
• 6.134 Stilla Technologies
• 6.135 Sysmex Inostics
• 6.136 Tempus Labs, Inc.
• 6.137 Thermo Fisher Scientific
• 6.138 Todos Medical
• 6.139 Ultima Genomics
• 6.140 Variantyx
• 6.141 Vela Diagnostics
• 6.142 Veracyte
• 6.143 VolitionRX
• 6.144 Vortex Biosciences
• 6.145 Zhejiang Orient Gene Biotech

7 The Global Market for MDx Cancer

• 7.1 MDx Cancer - Global Market Overview by Country
  • 7.1.1 Table - Global Market by Country
  • 7.1.2 Chart - Global Market by Country
• 7.2 Global Market by Cancer Type - Overview
  • 7.2.1 Table - Global Market by Cancer Type
  • 7.2.2 Chart - Global Market by Cancer Type - Base/Final Comparison
  • 7.2.3 Chart - Global Market by Cancer Type - Base Year
  • 7.2.4 Chart - Global Market by Cancer Type -Final Year
  • 7.2.5 Chart - Global Market by Cancer Type - Share by Year
  • 7.2.6 Chart - Global Market by Cancer Type - Segment Growth
• 7.3 Global Market by Product Type - Overview
  • 7.3.1 Table - Global Market by Product Type
  • 7.3.2 Chart - Global Market by Product Type - Base/Final Comparison
  • 7.3.3 Chart - Global Market by Product Type - Base Year
  • 7.3.4 Chart - Global Market by Product Type -Final Year
  • 7.3.5 Chart - Global Market by Product Type - Share by Year
  • 7.3.6 Chart - Global Market by Product Type - Segment Growth
• 7.4 Global Market by Place - Overview
  • 7.4.1 Table - Global Market by Place
  • 7.4.2 Chart - Global Market by Place - Base/Final Comparison
  • 7.4.3 Chart - Global Market by Place - Base Year
  • 7.4.4 Chart - Global Market by Place -Final Year
  • 7.4.5 Chart - Global Market by Place - Share by Year
  • 7.4.6 Chart - Global Market by Place - Segment Growth

8 Global Market by Cancer Type

• 8.1 MDx Breast Cancer
  • 8.1.1 Table Breast Cancer Testing - by Country
  • 8.1.2 Chart - Breast Cancer Testing Growth
• 8.2 MDx Colorectal Cancer
  • 8.2.1 Table Colorectal Cancer Testing - by Country
  • 8.2.2 Chart - Colorectal Cancer Testing Growth
• 8.3 MDx Cervical Cancer
  • 8.3.1 Table Cervical Cancer Testing - by Country
  • 8.3.2 Chart - Cervical Cancer Testing Growth
• 8.4 MDx Lung Cancer
  • 8.4.1 Table Lung Cancer Testing - by Country
  • 8.4.2 Chart - Lung Cancer Testing Growth
• 8.5 MDx Prostate
  • 8.5.1 Table Prostate Testing - by Country
  • 8.5.2 Chart - Prostate Testing Growth
• 8.6 MDx Melanoma Cancer
  • 8.6.1 Table Melanoma Cancer Testing - by Country
  • 8.6.2 Chart - Melanoma Cancer Testing Growth
• 8.7 MDx Blood
  • 8.7.1 Table Blood Testing - by Country
  • 8.7.2 Chart - Blood Testing Growth
• 8.8 MDx Companion Dx Development
  • 8.8.1 Table Companion Dx Development - by Country
  • 8.8.2 Chart - Companion Dx Development Growth
• 8.9 MDx Other Cancer
  • 8.9.1 Table Other Cancer Testing - by Country
  • 8.9.2 Chart - Other Cancer Testing Growth

9 Global Market by Product Type

• 9.1 MDx Instruments
  • 9.1.1 Table Instruments - by Country
  • 9.1.2 Chart - Instruments Growth
• 9.2 MDx Reagents
  • 9.2.1 Table Reagents - by Country
  • 9.2.2 Chart - Reagents Growth
• 9.3 MDx Software and Services
  • 9.3.1 Table Software and Services - by Country
  • 9.3.2 Chart - Software and Services Growth

10 Global Market by Place

• 10.1 MDx Clinical Laboratory
  • 10.1.1 Table Clinical Laboratory - by Country
  • 10.1.2 Chart - Clinical Laboratory Growth
• 10.2 MDx Pharmaceutical
  • 10.2.1 Table Pharmaceutical - by Country
  • 10.2.2 Chart - Pharmaceutical Growth
• 10.3 MDx Research
  • 10.3.1 Table Research - by Country
  • 10.3.2 Chart - Research Growth

11 Cancer Treatment and Trials

• 11.1 FDA Approvals by Year and Application
• 11.2 Clinical Trials Starts
• 11.3 Prevalence of Cancer Treatments

12 Appendices

• 12.1 United States Medicare System: Clinical Laboratory Fees Schedule
• 12.2 The Most Used IVD Assays
• 12.3 The Highest Grossing Assays
• 12.4 FDA Approved Human Genetic Tests
• 12.5 FDA Approved Pharmacogenomics Tests